Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia 6Blast Crisis 6Leukemia, Myeloid, Accelerated Phase 5Leukemia, Myeloid, Acute 4Myeloproliferative Disorders 3Neoplasms by Histologic Type 2Neoplasms 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Bone Marrow Diseases 2Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Philadelphia Chromosome 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Cyclophosphamide 13fludarabine 9fludarabine phosphate 7Bendamustine Hydrochloride 5Rituximab 4Busulfan 4ibrutinib 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Bortezomib 3AP 1903 reagent 3tetulomab tetraxetan lu-177 2ponatinib 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Lutetium 2Etoposide 2Doxorubicin 2Brentuximab Vedotin 2Bone Marrow Transplantation 2pembrolizumab 1ibritumomab tiuxetan 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immune System Diseases × ponatinib × Lymphoid × Clear all
NCT01667133 2022-06-13

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Takeda

Phase 1/2 Completed
35 enrolled 36 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡